Investor relations

Clinical Laserthermia Systems (CLS) is listed on Nasdaq First North Growth Market. Our aim is to provide relevant and transparent information for analysts, investors and media with the latest financial reports, events, news and the development of CLS’s share.

Strategy Update Event on February 15

Watch the recording from this event here.

IR Contacts

Dan J. Mogren | CEO

Rolf Bornschein | CFO

Financial reports

Here you can view and download interim reports, full year reports and annual reports from CLS.

Press releases

Here you can find the regulatory notices published in accordance with the listing requirements of Nasdaq First North Stockholm where CLS’ shares are listed.

Investment case

CLS’ vision is that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to surgery for several patient groups. CLS’ treatment systems provide minimally invasive treatment for solid soft tissue tumors of the prostate and brain as well as for the treatment of epilepsy.

CLS’ use of laser ablation as a focal therapy is a high precision alternative that is safe and has fewer and less serious side effects than drugs and traditional surgery. In the USA and Europe alone, the current market for the minimally invasive treatment of prostate cancer is valued at over USD 35 billion with the global markets for the other indications targeted by CLS – glioblastoma and epilepsy – expected to be worth in excess of USD 7 billion by 2027.

Corporate governance

Good corporate governance is central to ensuring that a company is managed in the right way. At CLS, we are very meticulous about having good and clear corporate governance so that our investors feel confident in the company and in the decisions that are made.

The share

The CLS share was first listed on the Aktietorget stock exchange in 2009, but is since 2017 listed on Nasdaq First North Stockholm as CLS B.

Financial calendar

2023-05-19 Interim Report 1/23 January – March
2023-06-29 Annual General Meeting
2023-08-25 Interim Report 2/23 January – June
2023-11-17 Interim Report 3/23 January – September
2024-02-23 Year-end Report 2023

Subscribe to news from CLS

Make sure you get all the exciting information about CLS’ progress.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region